Realistically 645M in cash. Product is selling. Need to cut costs IMMEDIATELY and put up a For Sale sign. Europe and the rest of the world has value. As for as reps go, start interviewing elsewhere before the choice is made for you which is any second. Hopefully you’re not “emotionally” attached to Vascepa.
JT Needs To Sell Amarin Immediately
- Thread starter anonymous
- Start date
-
- Tags
- None
You are likely correct but the idea for us to start interviewing elsewhere right now is a comical suggestion. Unless you mean at Amazon / Walmart or CVS. Have you turned on the news? This economy and job market will suffer for months if not longer due to this situation. The Pharma world will at worst start hemorrhaging jobs soon and at best have hiring freezes through this year.
Let the rumors begin
In a note, Cowen's Ken Cacciatore (Outperform/$8) says Amarin (NASDAQ:AMRN) could be worth $20 a share based on $10 on Vascepa sales in Europe and $10 upon a successful appeal of the recent patent ruling opening the door for generic competition.
He also believes that the company should consider selling itself since its valuation is centered on ex-U.S. opportunities (i.e., $10 a share) and could include a contingent value right (CVR) that would pay out $10/share on a patent win, adding that Merck (NYSE
fizer (NYSE:and AstraZeneca (NYSE:could be potential suitors.I have a skype interview this week for a new job... places are hiring. You can do home study at home and training virtually through webex. Instead of assuming you can't make a move now, why not try?
Let the rumors begin
In a note, Cowen's Ken Cacciatore (Outperform/$8) says Amarin (NASDAQ:AMRN) could be worth $20 a share based on $10 on Vascepa sales in Europe and $10 upon a successful appeal of the recent patent ruling opening the door for generic competition.
He also believes that the company should consider selling itself since its valuation is centered on ex-U.S. opportunities (i.e., $10 a share) and could include a contingent value right (CVR) that would pay out $10/share on a patent win, adding that Merck (NYSE
So what if there is opportunity for profit in Europe. How does that help us keep our jobs in the US? That only helps stockholders (and even that is a big maybe).